Guggenheim Capital’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Guggenheim Capital’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,643	Closed	-$16K	–	3082
2016 Q3	$16K	Buy	2,643 +1,460	+123%	+$9K	﹤0.01%	2843
2016 Q2	$5K	Sell	1,183 -96	-8%	-$627	﹤0.01%	2867
2016 Q1	$13K	Sell	1,279 -923	-42%	-$18.3K	﹤0.01%	2856
2015 Q4	$65K	Buy	2,202 +745	+51%	+$22.5K	﹤0.01%	2880
2015 Q3	$46K	Buy	1,457 +436	+43%	+$20.9K	﹤0.01%	2859
2015 Q2	$60K	Buy	+1,021	New	+$72K	﹤0.01%	2948
2014 Q3	–	Sell	-1,235	Closed	-$111K	–	3222
2014 Q2	$111K	Sell	1,235 -410	-25%	-$25.1K	﹤0.01%	2992
2014 Q1	$88K	Buy	1,645 +265	+19%	+$8.75K	﹤0.01%	3049
2013 Q4	$35K	Buy	+1,380	New	+$32.9K	﹤0.01%	3089

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Guggenheim Capital's PTX Position: Q4 2016 in Review

Guggenheim Capital sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2016, closing a stake of 2,643 shares — an estimated $16K sold.

Guggenheim Capital first reported a position in PTX in Q4 2013 and held it in 9 quarters. The position peaked at $111K in Q2 2014. 34 funds tracked by Wall St. Rank hold PTX as of Q4 2016.

Guggenheim Capital reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
Guggenheim Capital sold 2,643 Pernix Therapeutics Holdings, Inc. shares in Q4 2016, an estimated $16K.
Guggenheim Capital first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2013 and held it in 9 quarters.
Guggenheim Capital's Pernix Therapeutics Holdings, Inc. position peaked at $111K in Q2 2014.
34 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.